Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer

Cell Cycle. 2010 May;9(9):1738-41. doi: 10.4161/cc.9.9.11347. Epub 2010 May 29.

Abstract

Gastrin-releasing peptide (GRP), the mammalian bombesin (BN), appears to be involved in the growth of several neoplasms. BN/GRP receptors (BN/GRP-Rs) are expressed in a variety of cancer cells and have limited distribution in normal human tissue. Thus inhibition of BN/GRP-Rs represents an attractive target for pharmacological treatment of some human malignancies. This review will focus on intracellular signaling pathways which have been characterized to mediate BN/GRP-dependent receptor biological effects as well as on various approaches to target BN/GRP-Rs for therapeutic and diagnostic interventions in human malignancies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Bombesin / analogs & derivatives
  • Bombesin / antagonists & inhibitors
  • Bombesin / metabolism
  • Gastrin-Releasing Peptide / analogs & derivatives
  • Gastrin-Releasing Peptide / antagonists & inhibitors
  • Gastrin-Releasing Peptide / metabolism
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / therapy*
  • Receptors, Bombesin / antagonists & inhibitors*
  • Receptors, Bombesin / metabolism
  • Signal Transduction

Substances

  • Receptors, Bombesin
  • Gastrin-Releasing Peptide
  • Bombesin